Article Text

Download PDFPDF
Acute severe thrombocytopenia after treatment with ReoPro (abciximab)
  1. R Butler,
  2. P J B Hubner
  1. Departmentt of Cardiology, Glenfield Hospital, Groby Road, Leicester LE3 9QP, UK
  1. Dr Butler email: r.butler{at}


ReoPro (abciximab) is an extremely potent inhibitor of the glycoprotein IIb/IIIa receptor, the final common pathway of platelet activation and aggregation. Its main role is the maintenance of coronary patency after suboptimal results with coronary intervention. However, one of the complications of this treatment is excessive bleeding, a problem which may be compounded by a rare idiosyncratic thrombocytopenic reaction. A severe episode of thrombocytopenia in a 64 year old man is described; he was treated with ReoPro for a right coronary stenosis which had not been resolved by angioplasty. His platelet level dropped quickly and only improved after 20 units of platelets were given.

  • ReoPro
  • abciximab
  • platelets
  • thrombocytopenia
  • interventional cardiology

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.